Allstate Corporation’s CytomX Therapeutics CTMX Stock Holding History

Allstate Corporation’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$88.7K	Buy	+23,655	New	+$90.3K	﹤0.01%	1328

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Allstate Corporation's CTMX Position: Q2 2026 in Review

Allstate Corporation opened a new position in CytomX Therapeutics (CTMX) in Q2 2026: 23,655 shares worth $88.7K. The stake represents ﹤0.01% of the portfolio and ranks #1328 among its holdings.

179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

Allstate Corporation held 23,655 shares of CytomX Therapeutics worth $88.7K as of Q2 2026.
CytomX Therapeutics was a new Allstate Corporation position in Q2 2026.
CytomX Therapeutics made up ﹤0.01% of Allstate Corporation's portfolio in Q2 2026, its #1328 holding.
179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Allstate Corporation's 13F filing for Q2 2026, filed 13 Aug 2026.